253 related articles for article (PubMed ID: 17244360)
61. Modern diagnosis and management of hepatocellular carcinoma.
Marrero JA; Welling T
Clin Liver Dis; 2009 May; 13(2):233-47. PubMed ID: 19442916
[TBL] [Abstract][Full Text] [Related]
62. The application of proteomics in different aspects of hepatocellular carcinoma research.
Xing X; Liang D; Huang Y; Zeng Y; Han X; Liu X; Liu J
J Proteomics; 2016 Aug; 145():70-80. PubMed ID: 27072111
[TBL] [Abstract][Full Text] [Related]
63. Serum anti-Ku86 is a potential biomarker for early detection of hepatitis C virus-related hepatocellular carcinoma.
Nomura F; Sogawa K; Noda K; Seimiya M; Matsushita K; Miura T; Tomonaga T; Yoshitomi H; Imazeki F; Takizawa H; Mogushi K; Miyazaki M; Yokosuka O
Biochem Biophys Res Commun; 2012 May; 421(4):837-43. PubMed ID: 22554520
[TBL] [Abstract][Full Text] [Related]
64. Proteomic-based approach for the identification of tumor markers associated with hepatocellular carcinoma.
Shalhoub P; Kern S; Girard S; Beretta L
Dis Markers; 2001; 17(4):217-23. PubMed ID: 11790889
[TBL] [Abstract][Full Text] [Related]
65. Hepatocellular carcinoma of the liver.
Block T; Mehta AS; London WT
Cancer Biomark; 2010; 9(1-6):375-83. PubMed ID: 22112485
[TBL] [Abstract][Full Text] [Related]
66. A Computational Selection of Metabolite Biomarkers Using Emerging Pattern Mining: A Case Study in Human Hepatocellular Carcinoma.
Poezevara G; Lozano S; Cuissart B; Bureau R; Bureau P; Croixmarie V; Vayer P; Lepailleur A
J Proteome Res; 2017 Jun; 16(6):2240-2249. PubMed ID: 28447453
[TBL] [Abstract][Full Text] [Related]
67. Role of microRNA in the diagnosis and therapy of hepatocellular carcinoma: a new frontier.
Tsoulfas G
Microrna; 2014; 3(3):137-43. PubMed ID: 25541913
[TBL] [Abstract][Full Text] [Related]
68. Hepatocellular Carcinoma Genetic Classification.
Lominadze Z; Shaik MR; Choi D; Zaffar D; Mishra L; Shetty K
Cancer J; 2023 Sep-Oct 01; 29(5):249-258. PubMed ID: 37796642
[TBL] [Abstract][Full Text] [Related]
69. Liquid biopsy in the clinical management of hepatocellular carcinoma.
von Felden J; Garcia-Lezana T; Schulze K; Losic B; Villanueva A
Gut; 2020 Nov; 69(11):2025-2034. PubMed ID: 32883873
[TBL] [Abstract][Full Text] [Related]
70. Tumor biopsy and patient enrollment in clinical trials for advanced hepatocellular carcinoma.
Rimassa L; Reig M; Abbadessa G; Peck-Radosavljevic M; Harris W; Zagonel V; Pastorelli D; Rota Caremoli E; Porta C; Damjanov N; Patel H; Daniele B; Lamar M; Schwartz B; Goldberg T; Santoro A; Bruix J
World J Gastroenterol; 2017 Apr; 23(13):2448-2452. PubMed ID: 28428725
[TBL] [Abstract][Full Text] [Related]
71. Is the American Association for the Study of Liver Diseases recommendation for hepatocellular carcinoma screening a cul-de-sac?
Braillon A
World J Gastroenterol; 2013 Jun; 19(21):3369-70. PubMed ID: 23745043
[TBL] [Abstract][Full Text] [Related]
72. Using Serial Analysis of Gene Expression to identify tumor markers and antigens.
Riggins GJ
Dis Markers; 2001; 17(2):41-8. PubMed ID: 11673650
[TBL] [Abstract][Full Text] [Related]
73. The Impact of New Technologic and Molecular Advances in the Daily Practice of Gastrointestinal and Hepatobiliary Pathology.
Xue Y; Farris AB; Quigley B; Krasinskas A
Arch Pathol Lab Med; 2017 Apr; 141(4):517-527. PubMed ID: 28157407
[TBL] [Abstract][Full Text] [Related]
74. Cytokines as tumour markers.
Whicher IT; Banks RE
Scand J Clin Lab Invest Suppl; 1995; 221():122-44. PubMed ID: 7652486
[No Abstract] [Full Text] [Related]
75. Risk factors for hepatocellular carcinoma may impair the performance of biomarkers: a comparison of AFP, DCP, and AFP-L3.
Volk ML; Hernandez JC; Su GL; Lok AS; Marrero JA
Cancer Biomark; 2007; 3(2):79-87. PubMed ID: 17522429
[TBL] [Abstract][Full Text] [Related]
76. New perspectives and strategy research biomarkers for hepatocellular carcinoma.
Saffroy R; Pham P; Reffas M; Takka M; Lemoine A; Debuire B
Clin Chem Lab Med; 2007; 45(9):1169-79. PubMed ID: 17635075
[TBL] [Abstract][Full Text] [Related]
77. Cancer testis antigen burden (CTAB): a novel biomarker of tumor-associated antigens in lung cancer.
Seager RJ; Senosain MF; Van Roey E; Gao S; DePietro P; Nesline MK; Dash DP; Zhang S; Ko H; Hastings SB; Strickland KC; Previs RA; Jensen TJ; Eisenberg M; Caveney BJ; Severson EA; Ramkissoon S; Conroy JM; Pabla S
J Transl Med; 2024 Feb; 22(1):141. PubMed ID: 38326843
[TBL] [Abstract][Full Text] [Related]
78. Second-line treatment of advanced hepatocellular carcinoma: Time for more individualized treatment options?
Rajappa S; Rau KM; Dattatreya PS; Ramaswamy A; Fernandes P; Pruthi A; Cheng R; Lukanowski M; Huang YH
World J Hepatol; 2022 Jun; 14(6):1074-1086. PubMed ID: 35978665
[TBL] [Abstract][Full Text] [Related]
79. A maternal high-fat diet induces fetal origins of NASH-HCC in mice.
Takiyama T; Sera T; Nakamura M; Hoshino M; Uesugi K; Horike SI; Meguro-Horike M; Bessho R; Takiyama Y; Kitsunai H; Takeda Y; Sawamoto K; Yagi N; Nishikawa Y; Takiyama Y
Sci Rep; 2022 Jul; 12(1):13136. PubMed ID: 35907977
[TBL] [Abstract][Full Text] [Related]
80. Serum gamma-glutamyl transpeptidase-to-platelet ratio (GPR) can predict the prognosis of hepatocellular carcinoma: a meta-analysis and systematic review.
Ma C; Wang N; Ma H; Song K; Yu R; Chen H
Transl Cancer Res; 2022 Apr; 11(4):745-753. PubMed ID: 35571666
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
